Research Trials

If you have any questions or are interested in participating in one of our clinical trials, please jot down the trial number and contact your Nebraska Cancer Specialists medical oncologist or a member of our clinical research team at 402.334.4773, or email us at

Download All Current Trials
  • Cancer Type:

  • Biomarker:

  • Phase:

  • Keyword:

  • GSK Azur-2

    Phase 3 study of Perioperative Dostarlimab Monotherapy vs SOC in participants with Untreated T4N0 or Stage III dMMR/MSI H Resectable Colon Cancer

    Cancer Type: Colorectal

    Lines of Therapy: 1

    Biomarkers: dMMR

    Phase: 3

    View Details on
  • SGNTUC-028

    A randomized, double-blind, phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for metastatic HER2+ breast cancer (HER2CLIMB-05)

    Cancer Type: BREAST

    Lines of Therapy: 3

    Biomarkers: HR, HER2+

    Phase: 3

    View Details on
  • Serminox, SMX 22-002, Elaine III

    A Phase 3 Study comparing the efficacy and safety of the combination of Lasofoxifene and Abemaciclib to the combination of Fulvestrant and Abemaciclib for the treatment of pre and post menopausal women and men with locally advanced or metastatic ER+/Her2- Breast cancer with ESR1 Mutation

    Cancer Type: BREAST

    Biomarkers: ESR1

    Phase: 3

  • AstraZeneca Triton

    A Phase 3b, Study to assess the efficacy of Durvalumab plus Trememlimumab vs Pembrolizumab in combination with platinum based chemotherapy for 1st line treatment in metastatic NSCLC patients with non-squamous histology who have mutations and/or co-mutations in STK11, KEAP1, or KRAS

    Cancer Type: Lung NSCLC

    Biomarkers: STK11, KEAP1, KRAS

    Phase: 3

  • VMT-a-NET

    Phase 1/2a first in human study of VMTaNET Targeted Alpha Particle Therapy for advanced SSTR2 Positive Neuroendocrine Tumors

    Cancer Type: Neuroendocrine

    Biomarkers: SSTR2

    View Details on
  • SLC-391-102, Skylite

    Phase 1b/2 study of SLC-391, an AXL inhibitor, in ccombination with pembrolizumab in subjects wiht advanced or meastatic NSCLC

    Cancer Type: Lung NSCLC

    Lines of Therapy: 3, 2, 4

    Biomarkers: PD-L1+

    Phase: 1b, 2

    View Details on
  • PLB1004 - I (US01-BAB22228)

    Phase 1, open label, multidose, dose escalation and expansion study of the oral EGFR inhibitor PLB1004 in NSCLC

    Cancer Type: Lung NSCLC

    Lines of Therapy: 3, 2

    Biomarkers: EGFR

    Phase: 1

    View Details on
  • NKT2152-101 substudy only

    A Phase I/II, open label dose escalation and expansion trial of NKT2152, an orally administered HIF-2a inhibitor, to investigate safety, pharmacokinetics, pharmacodynamics, and clinical activity in patients with advanced clear cell renal cell carcinoma

    Cancer Type: Renal

    Phase: 1, 2

    View Details on
  • PROCLAIM (201707770)

    Phase 3 Randomized Placebo controlled double blind study of Romiplostim for the treatment of chemotherapy induced thrombocytopenia in patients receiving chemotherapy for treatment of NSCLC, Ovarian, Breast Cancer

    Cancer Type: Lung NSCLC, BREAST, OVARIAN

    Phase: 3

    View Details on
  • REC-4881-221, Recursion

    Phase II, open label stufy of REC 4881 in participants with unresectable locally advanced or metastatic tumors with AXIN1 or APC mutations

    Cancer Type: Solid tumor

    Biomarkers: AXIN1, APC, APN

    Phase: 2

    View Details on

Meet DOT.

Skip to content